ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
Browsing: Basic > Drug Development
Cerebral malaria is the most severe neurological complication of Plasmodium falciparum infection. Here, the authors discuss how NRG-1 could attenuate brain injury and mortality.
In this interview, take a look behind the scenes of a recent Future Microbiology paper on the role of transition metal control in E. coli virulence with author, Jeffrey Henderson.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.
Small-molecule compounds designed to tag the cell surface of Gram-negative bacteria and trigger an immunological response have shown promise.
In top-line results from a Phase IIa study, Abivax has reported mixed data, although ABX464 did appear to reduce HIV DNA in blood and rectal samples at a higher dose.
The US FDA has approved Zemdri for use in adults with complicated urinary tract infections; however, the agency has also issued a response for bloodstream infections noting there isn’t substantial evidence of Zemdri’s effectiveness.
Take a look behind the scenes of a recent Future Virology review entitled ‘Antiviral therapeutic approaches for human rhinovirus infections’ as we ask author Peter Barlow about antivirals, antibodies and the host response.